
News|Articles|May 1, 2002
Clarification, strengthening of ziprasidone QTc prolongation warning.
Pfizer has issued a "Dear Healthcare Professional" letter to clarify and strengthen contraindications with its antipsychotic agent ziprasidone HCl (Geodon).
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
FAQ: The uncertain future of enhanced ACA premium subsidies and what it means for U.S. healthcare
2
Myqorzo is now available for rare heart condition at a $108,400 annual price
3
Could GLP-1s help with cognitive symptoms, pychosis of schizophrenia?
4
When it comes to quality measures, fewer is viewed as better, says Ben Shirley of PQA | Part 2
5























